Estimating Causal Treatment Effects from Longitudinal HIV Natural History Studies Using Marginal Structural Models

Summary.  Several recently completed and ongoing studies of the natural history of HIV infection have generated a wealth of information about its clinical progression and how this progression is altered by therepeutic interventions and environmental factors. Natural history studies typically follow prospective cohort designs, and enroll large numbers of participants for long‐term prospective follow‐up (up to several years). Using data from the HIV Epidemiology Research Study (HERS), a six‐year natural history study that enrolled 871 HIV‐infected women starting in 1993, we investigate the therapeutic effect of highly active antiretroviral therapy regimens (HAART) on CD4 cell count using the marginal structural modeling framework and associated estimation procedures based on inverse‐probability weighting (developed by Robins and colleagues). To evaluate treatment effects from a natural history study, specialized methods are needed because treatments are not randomly prescribed and, in particular, the treatment‐response relationship can be confounded by variables that are time‐varying. Our analysis uses CD4 data on all follow‐up visits over a two‐year period, and includes sensitivity analyses to investigate potential biases attributable to unmeasured confounding. Strategies for selecting ranges of a sensitivity parameter are given, as are intervals for treatment effect that reflect uncertainty attributable both to sampling and to lack of knowledge about the nature and existence of unmeasured confounding. To our knowledge, this is the first use in “real data” of Robins's sensitivity analysis for unmeasured confounding ( Robins, 1999a , Synthese121, 151–179). The findings from our analysis are consistent with recent treatment guidelines set by the U.S. Panel of the International AIDS Society ( Carpenter et al., 2000 , Journal of the American Medical Association280, 381–391).

[1]  D. Rubin Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .

[2]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[3]  Joshua D. Angrist,et al.  Identification of Causal Effects Using Instrumental Variables , 1993 .

[4]  J. Robins,et al.  Analysis of semiparametric regression models for repeated outcomes in the presence of missing data , 1995 .

[5]  James M. Robins,et al.  Causal Inference from Complex Longitudinal Data , 1997 .

[6]  J. Heckman Instrumental Variables: A Study of Implicit Behavioral Assumptions Used in Making Program Evaluations. , 1997 .

[7]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[8]  D. Vlahov,et al.  Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. , 1997, American journal of epidemiology.

[9]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[10]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[11]  J. Robins,et al.  Estimation of the Causal Effect of a Time-Varying Exposure on the Marginal Mean of a Repeated Binary Outcome , 1999 .

[12]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[13]  L A Kalish,et al.  The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. , 1999, AIDS.

[14]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[15]  A. Mocroft,et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.

[16]  J. Pearl Causality: Models, Reasoning and Inference , 2000 .

[17]  A. Dawid Causal Inference without Counterfactuals , 2000 .

[18]  James M. Robins,et al.  Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .

[19]  Causal Inference Without Counterfactuals: Comment , 2000 .

[20]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[21]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[22]  J. Robins,et al.  Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .

[23]  James M. Robins,et al.  Association, Causation, And Marginal Structural Models , 1999, Synthese.